Health Canada pre-market guidance for machine-learning medical devices: AI evidence duties for healthcare buyers now explicit.
In a significant development for Canadian health technology buyers and decision-makers, Health Canada has finalised its rules on the approval of machine learning (ML) medical devices, specifically requiring buyers to demonstrate evidence that these complex technologies are safe and effective before they can be put into practice. This new requirement is part of an effort by the regulator to ensure that patients receive high-quality healthcare and to protect healthcare professionals from liability claims when ML devices fail or mislead.
For health insurance firms and financial services companies, particularly in Canada and the UK, this change demands immediate action because it sharpens the capability risk faced by these organisations. As buyers of AI solutions, they must demonstrate proof that any ML medical device works as promised for their patients, which means they need to evaluate not just the technology itself but also its potential impact on patient outcomes. If they fail to do so and a device malfunctions or provides misleading results, the consequences can be severe: reputational damage, legal liability, and financial losses.
To address these risks, prudent health buyers must now take steps to demonstrate evidence of AI capability and effectiveness in three key areas: clinical utility (the technology’s ability to achieve its intended medical purpose), safety (the risk of harm associated with device use), and performance (the level of accuracy or precision achieved). They should also consider the potential for bias, transparency, and explainability within ML algorithms. This may require partnering with healthcare experts who can help them understand the scientific validity and reliability of these complex technologies.
Straven & Co stands ready to support buyers in evaluating AI claims objectively by examining AI decisions before they are acted upon, using a unique blend of technical expertise and industry insight. Our independent validation process assesses not only the device itself but also its potential impact on patient outcomes, organisational governance, and legal exposure, delivering a plain verdict: proceed, proceed with conditions, or do not.